PCSK9 is a promising prognostic marker in patients with advanced NSCLC

  • Aldo BonaventuraEmail author
  • Francesco Grossi
  • Fabrizio Montecucco
Letter to the Editors


Author contribution

AB, FG, and FM equally contributed to the writing and revision of the manuscript draft and approved the final version.


This study was supported by a grant from the Italian Ministry of Health to the Italian Cardiovascular Network (#2754291) and a grant from the Fondazione CARIGE to Prof. Fabrizio Montecucco. The PD-1/PD-L1 analyses were supported by a grant from Compagnia San Paolo (SC: 2017-0529).

Compliance with ethical standards

Conflict of interest

Francesco Grossi has consulting/advisory relationship with and received honoraria from Bristol-Myers Squibb, Merck Sharp and Dohme, and Pierre Fabre and has consulting/advisory relationship with AstraZeneca and Roche. All other authors declare that there are no conflicts of interest.

Ethical approval

The study was approved by the Institutional Review Board of IRCCS Ospedale Policlinico San Martino, Genoa, Italy (registry number: P.R. 191REG2015). The study was conducted in accordance with the Declaration of Helsinki and consistent with International Conference on Harmonization (ICH) Guidelines for Good Clinical Practice.

Informed consent

Prior to inclusion in the study, all patients gave written, informed consent to the use of their samples and data for research and scientific publications.


  1. 1.
    Li P, Che G (2019) PD-L1 expression levels should be considered when identifying risk factors in NSCLC patients treated with nivolumab. Cancer Immunol Immunother. CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Liberale L, Montecucco F, Camici GG, Dallegri F, Vecchie A, Carbone F et al (2017) Treatment with proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors to reduce cardiovascular inflammation and outcomes. Curr Med Chem 24:1403–1416CrossRefGoogle Scholar
  3. 3.
    Bonaventura A, Grossi F, Carbone F, Vecchie A, Minetti S, Bardi N et al (2019) Serum PCSK9 levels at the second nivolumab cycle predict overall survival in elderly patients with NSCLC: a pilot study. Cancer Immunol Immunother 68:1351–1358CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2020

Authors and Affiliations

  1. 1.First Clinic of Internal Medicine, Department of Internal MedicineUniversity of GenoaGenoaItaly
  2. 2.Pauley Heart Center, Division of Cardiology, Department of Internal MedicineVirginia Commonwealth UniversityRichmondUSA
  3. 3.Medical Oncology UnitFondazione IRCCS Ca’ Granda Ospedale Maggiore PoliclinicoMilanItaly
  4. 4.IRCCS Ospedale Policlinico San Martino Genova–Italian Cardiovascular NetworkGenoaItaly

Personalised recommendations